PDF(Pubmed)
Abstract：
BACKGROUND: The aim of this study is to characterize health related quality of life (HRQOL) in Japanese patients after bladder cancer surgery and to perform cross-cultural comparison between Japanese and American patients.
METHODS: Firstly, we cross-sectionally assessed HRQOL of 371 patients in Japan using the Bladder Cancer Index (BCI-Japanese). HRQOL of the four groups of patients (native bladder without intravesical therapy, native bladder with intravesicaltherapy, cystectomy with ileal conduit, and cystectomy with neobladder) were assessed. Secondly, we compared the Japanese with the American cohort (n = 315) from the original BCI paper. After adjusting for age and gender, the differences in each BCI subdomain score was analyzed.
RESULTS: Among Japanese patients, the urinary domain function score was significantly lower among the cystectomy with neobladder group, compared to the cystectomy with ileal conduit group (p < 0. 01). Despite this, the urinary bother was comparable between the two groups. Although there were apparent differences between Japanese and American patients, there were few differences in Urinary and Bowel HRQOL. In three of the four treatment groups (other than native bladder with intravesical therapy), Japanese patients were more likely than Americans to report poor sexual function (p < 0.05). However, Japanese patients were less likely than Americans to be bothered by their lower sexual function, regardless of treatment (p < 0.05).
CONCLUSIONS: HRQOL outcomes following treatment of bladder cancer in Japan are comparable to those in the USA, except for sexual functioning and sexual bother. The BCI can be used for cross-cultural assessments of HRQOL in bladder cancer patients.
METHODS: Firstly, we cross-sectionally assessed HRQOL of 371 patients in Japan using the Bladder Cancer Index (BCI-Japanese). HRQOL of the four groups of patients (native bladder without intravesical therapy, native bladder with intravesicaltherapy, cystectomy with ileal conduit, and cystectomy with neobladder) were assessed. Secondly, we compared the Japanese with the American cohort (n = 315) from the original BCI paper. After adjusting for age and gender, the differences in each BCI subdomain score was analyzed.
RESULTS: Among Japanese patients, the urinary domain function score was significantly lower among the cystectomy with neobladder group, compared to the cystectomy with ileal conduit group (p < 0. 01). Despite this, the urinary bother was comparable between the two groups. Although there were apparent differences between Japanese and American patients, there were few differences in Urinary and Bowel HRQOL. In three of the four treatment groups (other than native bladder with intravesical therapy), Japanese patients were more likely than Americans to report poor sexual function (p < 0.05). However, Japanese patients were less likely than Americans to be bothered by their lower sexual function, regardless of treatment (p < 0.05).
CONCLUSIONS: HRQOL outcomes following treatment of bladder cancer in Japan are comparable to those in the USA, except for sexual functioning and sexual bother. The BCI can be used for cross-cultural assessments of HRQOL in bladder cancer patients.
摘要：
背景：这项研究的目的是描述日本膀胱癌手术后患者的健康相关生活质量（HRQOL），并进行日本和美国患者之间的跨文化比较。
方法：首先，我们使用膀胱癌指数(BCI-Japan)对日本371例患者的HRQOL进行了横断面评估.四组患者的HRQOL（未经膀胱内治疗的天然膀胱，天然膀胱与膀胱内治疗，回肠导管膀胱切除术，和新膀胱切除术）进行评估。其次,我们从原始BCI论文中比较了日本人和美国人(n=315)。在调整了年龄和性别后，分析各BCI亚域评分的差异.
结果：在日本患者中，膀胱切除合并新膀胱组的尿区功能评分明显较低，与回肠导管膀胱切除术组相比（p<0。01).尽管如此,两组之间的排尿障碍相当。尽管日本和美国患者之间存在明显差异，泌尿和肠道HRQOL几乎没有差异。在四个治疗组中的三个（除了膀胱内治疗的天然膀胱），日本患者比美国人更有可能报告性功能差（p<0.05）。然而,日本患者比美国人更不容易被他们较低的性功能所困扰，与治疗无关（p<0.05）。
结论：日本膀胱癌治疗后的HRQOL结果与美国相当，除了性功能和性烦恼。BCI可用于膀胱癌患者HRQOL的跨文化评估。
方法：首先，我们使用膀胱癌指数(BCI-Japan)对日本371例患者的HRQOL进行了横断面评估.四组患者的HRQOL（未经膀胱内治疗的天然膀胱，天然膀胱与膀胱内治疗，回肠导管膀胱切除术，和新膀胱切除术）进行评估。其次,我们从原始BCI论文中比较了日本人和美国人(n=315)。在调整了年龄和性别后，分析各BCI亚域评分的差异.
结果：在日本患者中，膀胱切除合并新膀胱组的尿区功能评分明显较低，与回肠导管膀胱切除术组相比（p<0。01).尽管如此,两组之间的排尿障碍相当。尽管日本和美国患者之间存在明显差异，泌尿和肠道HRQOL几乎没有差异。在四个治疗组中的三个（除了膀胱内治疗的天然膀胱），日本患者比美国人更有可能报告性功能差（p<0.05）。然而,日本患者比美国人更不容易被他们较低的性功能所困扰，与治疗无关（p<0.05）。
结论：日本膀胱癌治疗后的HRQOL结果与美国相当，除了性功能和性烦恼。BCI可用于膀胱癌患者HRQOL的跨文化评估。
